Effective Suppression of Vascular Network Formation by Combination of Antibodies Blocking VEGFR Ligand Binding and Receptor Dimerization Tvorogov, D.; Anisimov, A.; Zheng, W.; Leppänen, V.; Tammela, T.; Laurinavicius, S.; Holnthoner, W.; Heloterä, H.; Holopainen, T.; Jeltsch, M.; Kalkkinen, N.; Lankinen, H.; Ojala, P.; Alitalo, K. , Cancer Cell, (2010) Abstract

Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation Bry, M.; Kivelä, R.; Holopainen, T.; Anisimov, A.; Tammela, T.; Soronen, J.; Silvola, J.; Saraste, A.; Jeltsch, M.; Korpisalo, P.; Carmeliet, P.; Lemström, K.; Shibuya, M.; Ylä-Herttuala, S.; Alhonen, L.; Mervaala, E.; , e.; Knuuti, J.; Alitalo, K. , Circulation, Volume 122, p.1725-33, (2010) Abstract

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis Heckman, C.A.; Holopainen, T.; Wirzenius, M.; Keskitalo, S.; Jeltsch, M.; Ylä-Herttuala, S.; Wedge, S.R.; Jürgensmeier, J.M.; Alitalo, K. , Cancer Research, Volume 68, p.4754-62, (2008) Abstract

Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry He, Y.; Rajantie, I.; Pajusola, K.; Jeltsch, M.; Holopainen, T.; Yla-Herttuala, S.; Harding, T.; Jooss, K.; Takahashi, T.; Alitalo, K. , Cancer Res, Volume 65, Issue 11, Molecular/Cancer Biology Laboratory and Ludwig Institute for Cancer Research, Biomedicum Helsinki and Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland, p.4739-46, (2005) Abstract